Conceptual Framework of Collateral-promoting Therapy for Coronary Artery Disease

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare:

For permissions and non-commercial reprint enquiries, please visit to start a request.

For author reprints, please email
Average (ratings)
No ratings
Your rating


Human coronary collateral circulation (CCC) serves as an alternative blood-conveying circuit to the ischaemic myocardium. Functional potentiation of CCC is considered as a therapeutic approach in patients with intractable angina for whom revascularisation procedures such as percutaneous coronary intervention and coronary artery bypass graft surgery are not indicated. Augmentation of CCC is established by collateral recruitment and growth. Nitrates and sarpogrelate are representative drugs that enhance collateral recruitment. Exercise, enhanced external counterpulsation and whole-body periodic acceleration accelerate and potentiate collateral growth via increased mechanical stress at pre-existent collateral arterioles. Granulocyte macrophage colony-stimulating factor and heparin favourably modulate the cascade of coronary collateral growth. Further experimental and clinical studies will be needed to create more sophisticated coronary collateral-promoting therapies.

Disclosure:The author has no conflicts of interest to declare.



Correspondence Details:Masatoshi Fujita, Professor of Human Health Sciences, Kyoto University Graduate School of Medicine, 53 Kawaharacho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. E:

Copyright Statement:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

Despite remarkable advances in revascularisation procedures such as percutaneous coronary intervention (PCI) and coronary bypass graft surgery (CABG), a considerable number of patients with intractable angina are not candidates for these procedures. Coronary collateral circulation (CCC) is an alternative blood-conveying circuit to potentially ischaemic myocardium. Promotion of CCC is a therapeutic strategy for these patients. Proof of concept has been established for arteriogenesis, namely coronary collateral growth.1 In addition, proof of mechanism has been accumulated regarding triggers of arteriogenesis.2 On the basis of the aforementioned recent progress in this field in terms of basic and clinical research, this article focuses on collateral-promoting therapy for coronary artery disease.

Recruitment of Coronary Collateral Circulation

There are two approaches to increasing coronary collateral blood flow, namely collateral recruitment and growth. Coronary collateral vessels gradually dilate after the establishment of a pressure gradient between collateral-providing and -receiving coronary arteries.3,4 Collateral recruitment is responsible for the walk-through phenomenon in angina patients with a well-developed collateral circulation.5 The principal mechanism of collateral recruitment is collateral flow-dependent dilation of pre-existing collateral vessels with several layers of muscular media.6


It is speculated that coronary collateral vessels largely respond to nitrates because of the depressed endothelial function of newly developed collateral vessels.7 Indeed, intravenous injection of nitroglycerin reversed functional regression of well-developed collateral vessels in FranklinÔÇÖs model of coronary collateral development.8 We found that the administration of sublingual nitroglycerin improved wall motion in the infarct area perfused by a significant collateral circulation, which was presumably due to increased collateral blood flow.9 We also found that pre-treatment through the oral administration of 10mg of isosorbide dinitrate ameliorated treadmill exercise capacity more markedly in angina patients with a well-developed collateral circulation than in those without collateral circulation.10


Serotonin (5-hydroxytryptamine [5-HT]) released from platelets dilates arteries via 5-HT1B receptors in endothelial cells, which are coupled to the activation of endothelial nitric oxide synthase, and constricts them via 5-HT2A receptors in vascular smooth-muscle cells (see Figure 1). A small dose of serotonin dilates the coronary artery, while a large dose of serotonin constricts it in normal subjects. By contrast, both small and large doses of serotonin constrict coronary and collateral arteries in patients with coronary atherosclerosis and well-developed collateral circulation, which is presumably due to depressed endothelial function.11 We reported that orally administered sarpogrelate, a 5-HT2A antagonist, improved exercise capacity as a result of increased collateral blood flow to ischaemic areas in angina patients with well-developed collaterals.12 These beneficial effects of sarpogrelate were re-confirmed in a subsequent multicentre clinical study.13 The chronic administration of sarpogrelate induced not only collateral recruitment but also collateral growth (arteriogenesis) in rabbit hind-limb ischaemia14 and diabetic mouse hind-limb ischaemia.15 The possible mechanism of sarpogrelate-induced arteriogenesis is as follows: the increased blood flow mediated by sarpogrelate augments the fluid and pulsatile shear stress at the site of pre-existent collateral vessels, leading to arteriogenesis.16 Thus, chronic administration of sarpogrelate effectively enhances collateral blood flow through both collateral recruitment and arteriogenesis.

Coronary Collateral Growth

The time course of arteriogenesis, namely collateral growth, is summarised as molecular and cellular events in a monograph.17 The principal mechanism of arteriogenesis is proliferation of vascular smooth-muscle cells in the pre-existent collateral vessels, which is accomplished by a complicated cascade triggered by increased shear stress on vascular endothelial cells.1,2,17


The beneficial effects of exercise training on coronary collateral growth remain controversial. In the absence of significant coronary stenosis, there is no pressure gradient across the pre-existent coronary collateral circulation. In this haemodynamic milieu, exercise does not increase collateral flow. By contrast, coronary collateral flow increases markedly with exercise stress in the presence of a completely occluded receiving coronary artery of collateral circulation because of vasodilation of the resistance vessels in the area perfused by the occluded artery. Increased collateral flow causes arteriogenesis.

To ensure the augmentation of collateral flow by exercise and to maximise the exercise benefit, the following issues must be addressed. First, both a non-stenosed collateral-providing artery18 and an occluded collateral-receiving artery19 are indispensable to establish a significant pressure gradient across the collateral network. Second, the absence of previous myocardial infarction and the presence of viable myocardium are important20 because intact microcirculation in the area perfused by the occluded artery is required for adequate coronary collateral flow. Thus, it is conceivable that exercise training in patients with chronic stable angina is facilitated if the above-mentioned conditions are fulfilled.21

Enhanced External Counterpulsation

Enhanced external counterpulsation (EECP) is well appreciated as a less invasive therapeutic modality for ischaemic heart disease. EECP is conducted by electrocardiogram (ECG)-gated sequential inflation and rapid deflation of three sets of cuffs wrapped around the lower extremities. EECP enhances the aortic diastolic pressure by driving the pressure of coronary and collateral blood flow, leading to increased intravascular fluid and pulsatile shear stress. EECP also decreases myocardial oxygen consumption as a result of systolic unloading. On the basis of the aforementioned conceptual framework, Arora et al. showed that a total of 35-45 minutes of EECP effectively and safely improved exercise capacity and angina symptoms in patients with stable angina.22 There are two possible mechanisms underlying the increased blood flow to potentially ischaemic myocardium. First, it is likely that EECP treatment enhances arteriogenesis as a result of increased coronary collateral blood flow and the resultant augmented intravascular fluid and pulsatile shear stress, which is the case in intra-aortic balloon pumping.23 Alternatively, endothelial dysfunction is responsible for the pathogenesis of decreased coronary flow reserve.24 Accordingly, improvement of coronary endothelial function with EECP would enhance coronary flow reserve in the area perfused by the severely narrowed coronary artery and/or collateral vessels.25

Whole-body Periodic Acceleration

Sackner invented a horizontal motion platform, which was inspired by a mother hugging and bouncing her baby up and down.26,27 The platform moves the body repetitively in the direction from head to foot approximately 140 times per minute. This stimulates the release of biologically active substances such as nitric oxide.26 The physiological effects of these mediators released during a 45-minute treatment with the motion platform have been proved to be comparable to the effects of moderate to strenuous exercise.27

We hypothesised that whole-body periodic acceleration (WBPA) increases the pulsatile shear stress on the pre-existing coronary collateral arterioles in patients with severe coronary artery stenosis, and that arteriogenesis resulting from the increased shear stress improves exercise capacity, myocardial ischaemia and left ventricular (LV) function. We also supposed that these beneficial effects on the blood flow to ischaemic myocardium would be accentuated by the improved coronary flow reserve in the area supplied by a severely narrowed coronary artery and/or collateral vessels28 because the WBPA treatment improves vascular endothelial function.29 Indeed, in 13 angina patients who were not indicated for PCI and/or CABG, 20 sessions of 45 minutes of WBPA treatment significantly increased the mean treadmill exercise time in the standard Bruce protocol until 0.1mV ST depression from 4.4 to 6.7 minutes, and the double product at 0.1mV ST depression from 15,400 to 18, A resting radionuclear study revealed a significant increase in the LV ejection fraction from 50 to 55% along with a decrease in LV end-diastolic volume index from 73 to 60ml/m2. Adenosine myocardial scintigraphy demonstrated that both ischaemic and hibernating myocardia became smaller with the WBPA treatment.30 Thus, WBPA treatment will open a new field of therapeutic strategies for patients with intractable angina.

Granulocyte Macrophage Colony-stimulating Factor

Schaper emphasised the importance of monocytes/macrophages for arteriogenesis.17 Accumulated and activated monocytes produce and release a variety of angiogenic growth factors, which is potentiated by granulocyte macrophage colony-stimulating factor (GM-CSF) upregulation in endothelial cells at pre-existent collateral arterioles as a result of increased intravascular shear stress.31 It has been documented that locally delivered GM-CSF accelerates arteriogenesis by augmenting the function of monocytes/macrophages.32 Seiler et al. translated these experimental findings to clinical situations.33,34 Although GM-CSF treatment increased the collateral flow index in these studies, coronary plaque rupture occurred in two of seven GM-CSF-treated patients.34


Heparin plays important roles in arteriogenesis and angiogenesis, the former of which was predominant in Franklin's model with brief repetitive coronary occlusions.35 However, heparin alone does not act as an angiogenic factor, but may potentiate the effects of several angiogenic growth factors released from activated monocytes at the site of pre-existent coronary collateral arteries.36 We investigated heparin treatment combined with exercise in 16 patients with angiographically documented coronary artery disease and chronic angina. Each patient undertook strenuous exercise twice a day for 10 days. Ten patients were intravenously injected with heparin 10-20 minutes before each exercise session. The double product indicating myocardial oxygen consumption at 0.1mV ST depression remained unchanged in controls, but increased by 19% in the heparin-treated patients. Repeated coronary angiography revealed actual development of collateral vessels.37 Beneficial effects of heparin on promoting arteriogenesis have been confirmed in animal38 and clinical studies.36,39-41 Heparin exercise treatment is inexpensive; however, heparin-induced thrombocytopenia must be closely checked in clinical practice.

Not Collateral- but Angiogenesis-promoting Therapy

In contrast to the above-mentioned collateral-promoting therapy, other approaches are based on the concept of augmentation of not arteriogenesis but angiogenesis in the area perfused by the ischaemia-related coronary artery. Henry et al. have demonstrated in a double-blind, placebo-controlled trial that intravenous administration of recombinant human vascular endothelial growth factor (VEGF) did not improve exercise tolerance and angina symptoms beyond the effects seen with placebo.42 Three multicentre randomised controlled clinical studies evaluating the effect of intracoronary injection of autologous bone-marrow-derived mononuclear cells on LV functional recovery in acute myocardial infarction patients with primary PCI revealed inconsistent results.43-45 Two trials showed moderate but significant improvement in the LV ejection fraction,43,44 while there were no beneficial effects in the third trial.45 The failure or equivocal benefits of these approaches may be interpreted as follows.

First, collateral blood flow is mainly enhanced by arteriogenesis. The contribution of angiogenesis induced by VEGF administration or various angiogenic growth factors included in the fluid of transplanted bone marrow is minimal or absent.46 Second, angiogenic effects resulting from a single bolus administration of VEGF45 or several growth factors secreted by transplanted cells will disappear during a relatively short time period.47,48

Low-energy shock-wave therapy was introduced and developed by Shimokawa et al. as an alternative mechanical application to increase coronary blood flow to ischaemic myocardium. Extracorporeal shockwave therapy is now frequently utilised to fragmentise kidney and urethra stones. Approximately 10% of the energy used for the treatment of urolithiasis is applied for cardiac shock-wave therapy.49,50 In a pig model of myocardial ischaemia with an ameroid constrictor on the coronary artery, low-energy shock-wave therapy to potentially ischaemic myocardium significantly increased the capillary density and VEGF expression along with regional myocardial functional improvement.49 Subsequently, in a double-blind placebo-controlled study of patients with intractable angina, the efficacy and safety of low-energy shock-wave therapy were confirmed.50 The underlying mechanism of the treatment is considered to be augmentation of angiogenesis in the ischaemic area. Although such original treatment is challenging, the potentiation of angiogenesis may be limited to enhancing coronary perfusion for the above-mentioned reason.46

Summary and Future Perspectives

Figure 2 shows a schematic diagram of the proposed mechanisms for several of the collateral-promoting treatments described in this article. Promotion of arteriogenesis is an attractive therapeutic approach for patients with intractable angina. Further studies from various points of view are needed to realise a new collateral-promoting therapy in the near future.


  1. Heil M, Eitenm├╝ller I, Schmitz-Rixen T, Schaper W, Arteriogenesis versus angiogenesis: similarities and differences, J Cell Mol Med, 2006;10:45-55.
  2. Fujita M, Sasayama S, Coronary collateral growth and its therapeutic application to coronary artery disease, Circ J, 2010;74:1283-9.
  3. Fujita M, McKown DP, McKown MD, Franklin D, Coronary collateral regression in conscious dogs, Angiology, 1990;41:621-30.
  4. Cribier A, Korsatz L, Koning R, et al., Improved myocardial ischemic response and enhanced collateral circulation with long repetitive coronary occlusion during angioplasty: a prospective study, J Am Coll Cardiol, 1992;20:578-86.
  5. Tanaka K, Fujita M, Hirai T, et al., Improvement of ST segment depression by gradual recruitment of collateral circulation, Cardiology, 1990;77:17-24.
  6. Yamanishi K, Fujita M, Ohno A, Sasayama S, Importance of myocardial ischaemia for recruitment of coronary collateral circulation in dogs, Cardiovasc Res, 1990;24:271-7.
  7. Wright L, Homans DC, Laxson DD, et al., Effect of serotonin and thromboxane A2 on blood flow through moderately well developed coronary collateral vessels, J Am Coll Cardiol, 1992;19:687-93.
  8. Fujita M, McKown DP, McKown MD, Franklin D, Effects of glyceryl trinitrate on functionally regressed newly developed collateral vessels in conscious dogs, Cardiovasc Res, 1988;22: 639-47.
  9. Fujita M, Yamanishi K, Hirai T, et al., Significance of collateral circulation in reversible left ventricular asynergy by nitroglycerin in patients with relatively recent myocardial infarction, Am Heart J, 1990;120:521-8.
  10. Ohno A, Fujita M, Miwa K, et al., Importance of coronary collateral circulation for increased treadmill exercise capacity by nitrates in patients with stable effort angina pectoris, Cardiology, 1991;78:323-8.
  11. McFadden EP, Clarke JG, Davies GJ, et al., Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina, N Engl J Med, 1991;324:648-54.
  12. Tanaka T, Fujita M, Nakae I, et al., Improvement of exercise capacity by sarpogrelate as a result of augmented collateral circulation in patients with effort angina, J Am Coll Cardiol, 1998;32:1982-6.
  13. Kinugawa T, Fujita M, Lee JD, et al., Effectiveness of a novel serotonin blocker, sarpogrelate, for patients with angina pectoris, Am Heart J, 2002;144:e1.
  14. Hirose K, Fujita M, Marui A, et al., Combined treatment of sustained-release basic fibroblast growth factor and sarpogrelate enhances collateral blood flow effectively in rabbit hindlimb ischemia, Circ J, 2006;70:1190-94.
  15. Bir SC, Fujita M, Marui A, et al., New therapeutic approach for impaired arteriogenesis in diabetic mouse hindlimb ischemia, Circ J, 2008;72:633-40.
  16. Schaper W, Scholz D, Factors regulating arteriogenesis, Arterioscler Thromb Vasc Biol, 2003;23:1143-51.
  17. Schaper W, Theory of arteriogenesis. In: Schaper W, Schaper J (eds), Arteriogenesis, Dordrecht: Kluwer Academic Publishers, 2004;253-7.
  18. Fujita M, McKown DP, McKown MD, Franklin D, Effects of stenoses of donor arteries on collateral flow and regional myocardial function in conscious dogs with well-developed coronary collateral circulation, Coronary Artery Dis, 1991;2: 815-22.
  19. Rentrop KP, Cohen M, Blanke H, Phillips RA, Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects, J Am Coll Cardiol, 1985;5:587-92.
  20. Fujita M, Ohno A, Wada O, et al., Collateral circulation as a marker of presence of viable myocardium in patients with recent myocardial infarction, Am Heart J, 1991;122:409-14.
  21. Todd IC, Bradnum MS, Cooke MBD, Ballantyne D, Effects of daily high-intensity exercise on myocardial perfusion in angina pectoris, Am J Cardiol, 1991;68:1593-9.
  22. Arora RR, Chou TM, Jain D, et al., The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes, J Am Coll Cardiol, 1999;33:1833-40.
  23. Flynn MS, Kern MJ, Donohou TJ, et al., Alterations of coronary collateral blood flow velocity during intraaortic balloon pumping, Am J Cardiol, 1993;71:1451-5.
  24. Ludmer PL, Selwyn AP, Shook TL, et al., Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries, N Engl J Med, 1986;315:1046-51.
  25. Bonetti PO, Barsness GW, Keelan PC, et al., Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease, J Am Coll Cardiol, 2003;41:1761-8.
  26. Sackner MA, Gummels E, Adams JA, Nitric oxide is released into circulation with whole-body, periodic acceleration, Chest, 2005;127:30-39.
  27. Sackner MA, Gummels E, Adams JA, Effect of moderateintensity exercise, whole-body periodic acceleration, and passive cycling on nitric oxide release into circulation, Chest, 2005;128:2794-2803.
  28. Fukuda S, Shimada K, Kawasaki T, et al., ÔÇ£Passive exerciseÔÇØ whole body periodic acceleration: effects on coronary microcirculation, Am Heart J, 2010;159:620-26.
  29. Matsumoto T, Fujita M, Tarutani Y,et al., Whole-body periodic acceleration enhances brachial endothelial function, Circ J, 2008;72:139-43.
  30. Miyamoto S, Inoko M, Haruna T, et al., Treatment with whole body periodic acceleration with a horizontal motion platform reverses left ventricular remodeling in angina patients with old myocardial infarction (abstract), J Am Coll Cardiol, 2010;55:A120. E1126.
  31. Kosaki K, Ando J, Korenaga R, et al., Fluid shear stress increases the production of granulocyte-macrophage colonystimulating factor by endothelial cells via mRNA stabilization, Circ Res, 1998;82:794-802.
  32. Buschmann IR, Hoefer IE, van Royen N, et al., GM-CSF: a strong arteriogenic factor acting by amplification of monocyte function, Atherosclerosis, 2001;159:343-56.
  33. Seiler C, Pohl T, Wustmann K, et al., Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study, Circulation, 2001;104:2012-17.
  34. Zbinden S, Zbinden R, Meier P, et al., Safety and efficacy of subcutaneous-only granulocyte-macrophage colonystimulating factor for collateral growth promotion in patients with coronary artery disease, J Am Coll Cardiol, 2005;46: 1636-42.
  35. Fujita M, Kihara Y, Hasegawa K, et al., Heparin potentiates collateral growth but not growth of intramyocardial endarteries in dogs with repeated coronary occlusion, Int J Cardiol, 1999;70:165-70.
  36. Fujita M, Yamanishi K, Hirai T, et al., Comparative effect of heparin treatment with and without strenuous exercise on treadmill capacity in patients with stable effort angina, Am Heart J, 1991;122:453-7.
  37. Fujita M, Sasayama S, Asanoi H, et al., Improvement of treadmill capacity and collateral circulation as a result of exercise with heparin pretreatment in patients with effort angina, Circulation, 1988;77:1022-9.
  38. Arai Y, Fujita M, Marui A, et al., Combined treatment with sustained-release basic fibroblast growth factor and heparin enhances neovascularization in hypercholesterolemic mouse hindlimb ischemia, Circ J, 2007;71:412-17.
  39. Quyyumi AA, Diodati JG, Lakatos E, et al., Angiogenic effects of low molecular weight heparin in patients with stable coronary artery disease: a pilot study, J Am Coll Cardiol, 1993;22:635-41.
  40. Fujita M, Sasayama S, Kato K, et al., Prospective, randomized, placebo-controlled, double-blind, multicenter study of exercise with enoxaparin pretreatment for stable-effort angina, Am Heart J, 1995;129:535-41.
  41. Tateno S, Terai M, Niwa K, et al., Alleviation of myocardial ischemia after Kawasaki disease by heparin and exercise therapy, Circulation, 2001;103:2591-7.
  42. Henry TD, Annex BH, McKendall GR, et al., The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis, Circulation, 2003;107:1359-65.
  43. Schächinger V, Erbs S, Elsässer A, et al., Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction, N Engl J Med, 2006;355:1210-21.
  44. Assmus B, Honold J, Schächinger V, et al., Transcoronary transplantation of progenitor cells after myocardial infarction, N Engl J Med, 2006;355:1222-32.
  45. Lunde K, Solheim S, Aakhus S, et al., Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction, N Engl J Med, 2006;355:1199-1209.
  46. Fujita M, Tambara K, Recent insights into human coronary collateral development, Heart, 2004;90:246-50.
  47. Ziegelhoeffer T, Fernandez B, Kostin S, et al., Bone marrowderived cells do not incorporate into the adult growing vasculature, Circ Res, 2004;94:230-38.
  48. Kinnaird T, Stabile E, Burnett MS, et al., Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms, Circ Res, 2004;94:678-85.
  49. Nishida T, Shimokawa H, Oi K, et al., Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo, Circulation, 2004;110: 3055-61.
  50. Kikuchi Y, Ito K, Ito Y, et al., Double-blind and placebocontrolled study of the effectiveness and safety of extracorporeal cardiac shock wave therapy for severe angina pectoris, Circ J, 2010;74:589-91.